Atopic Dermatitis

Investigators believe drugs like etanercept and ustekinumab could reduce the risk of psoriatic arthritis in patients with moderate-to-severe chronic plaque psoriasis.

Investigators in China observed a substantial decrease in the number of severe cases after the arrival of the EV-A71 vaccine.

The decision was supported by 5 clinical trials that resulted in significant improvements in skin clearance, extent of disease, and severity.

Upadacitinib is now indicated for children 12 years and older, and can be used as a monotherapy or with topical corticosteroids.

Trials of CBP-201 for asthma and chronic rhinosinusitis with nasal polyps are ongoing, and early data from the atopic dermatitis trial were promising.

The skin disease was also linked to higher levels of glucosyl cholesterol which was strongly associated with disease severity.

The results suggested that the microbial changes were secondary in the pathogenesis of the skin disease.

Dr. Silverberg speaks of the recent FDA approval of the biologic for patients with moderate-to-severe atopic dermatitis.

Previous studies suggested that the disorder is caused by immunoglobulin G (IgG) antibodies against the NC16A domain of collagen XVII.

Recovery was often deemed rapid, with patients reporting post-surgical pain to be less severe than the pain of their disease.

A new investigation, which included the largest AGEP study cohort, concluded that the disease was also typically triggered by antimicrobials.

Treatment with the antibody also resulted in infections and drug reactions, prompting a call for larger and longer studies from investigators.

Investigators hypothesized that red cell distribution width to hemoglobin ratio could help in stratifying the risk of the skin condition in patients form the Singapore General Hospital.

Dr. Silverberg speaks of the desire for more inclusive studies and educational resources on skin of color by patients and physicians alike.

The decision was made after favorable phase 3 trial results of the biologic.

Investigators suggest that improvements to care could be made based on experiences and recommendations from patients with chronic hand eczema.

Data from the ADQoC Initiative show that patients with AD are often misdiagnosed or the severity of their disease was undertreated.

Dr. Amy Paller and colleagues noted high efficacy rates and minimal adverse events from biologic therapy.

Prior to the study, little was known on the relationship between the disease and fractures.

Investigators suggested systemic mental health monitoring could be beneficial for women who have atopic disease before pregnancy.

Investigators called for more studies which feature adequately powered trials of test-guided dietary exclusions.

The topical drug was associated with adverse events that were mainly localized to the application site and mild to moderate in nature.

The condition is rare, with limited epidemiological data and no standard treatment.

Significant 2-way interactions were found of atopic dermatitis with sleep disturbance as predictors of ≥75th percentile for poor task completion at 9 years of age.

Investigators called for prospective studies with longer time horizons to see if these associations persist throughout childhood.